Ozenoxacin: A Novel Topical Quinolone for Impetigo.

Christopher WrenEdward BellLea S Eiland

Published in: The Annals of pharmacotherapy (2018)

Ozenoxacin, the first nonfluorinated quinolone, is a safe, topical treatment for impetigo in patients 2 months of age and older. Although clinical trials demonstrate efficacy compared with placebo, comparative trials to current treatment options are needed to identify its therapeutic use.

Keyphrases

clinical trial
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
randomized controlled trial
wound healing
phase iii
patient reported outcomes
middle aged
replacement therapy